Article · 26 Aug 2024
Conference abstract
Assuring bioequivalence: pilot studies or dissolution?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
D evelopment of generic oral solid dosage forms that are equivalent to the innovator approved formulation is a challenging task for companies. As NCE development gets more expensive and time- consuming, innovators focus not just on getting a safe and effective drugs into the market but take into account the entire life cycle of the product. In many cases, this leads to complicated formulations, regimens and delivery systems to increase the barrier to generic competition. One of the tools that can be used by generic formulators is dissolution testing as an early predictor of in vivo performance. Dissolution testing is used in the drug development phase, both for new chemical entities (NCEs) and generic products, but can also be used as a tool for evaluating product quality. Variability issues and lack of scientific understanding of critical product attributes essential for bioequivalence have led to an excessive reliance on in vivo bioequivalence testing as the final proof of product performance. The proliferation of contract research organizations (CROs) in India undertaking studies on healthy human volunteers for the testing of bioequivalence between pharmaceutical formulations is proof to this development. Easy availability of volunteers and quick turnaround of results at a low price has led to indiscriminate use of humans as surrogates for evaluating pharmaceutical formulations, instead of dissolution testing being used as a surrogate to provide indirect assurance of in vivo performance. The regulatory requirement to submit failed BE studies as part of ANDAs may have an impact on the prevalent practice. PDF HTML
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 21 Aug 2023
Integration of in vitro biorelevant dissolution and in vivo bioequivalence study to in silico PBPK modelling of furosemide oral formulations to predict bioequivalence in dogs by PBBM approach
Research article · 31 Jul 2019
Predicting the Bioequivalence of Ciprofloxacin HCL Tablet-Brands Using In Vitro Dissolution and Rat Intestinal Permeability Tests
Conference abstract · 13 Mar 2017
Application of simultaneous dissolution-absorption apparatus for screening formulations before bioequivalence studies
Research article · 2010
Comparison of US and Japanese Regulations for Invitro Dissolution and Invivo Bioequivalence Studies
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Ranjani Nellore”
